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Burden of Uncontrolled Metabolic Risk Factors and Left Ventricular
Structure and Function in Patients With Type 2 Diabetes Mellitus
Peter Godsk Jørgensen, MD, PhD; Magnus Thorsten Jensen, MD, PhD; Tor Biering-Sørensen, MD, PhD; Rasmus Mogelvang, MD, PhD;
Thomas Fritz-Hansen, MD; Tina Vilsbøll, MD, DMSc; Peter Rossing, MD, DMSc; Jan Skov Jensen, MD, PhD, DMSc*
Background-—Type 2 diabetes mellitus is closely associated with metabolic risk factors that all contribute to impairment of the left
ventricle. The implications of having type 2 diabetes mellitus with well-controlled metabolic risk factors compared to an increasing
burden of uncontrolled metabolic risk factors on left ventricular structure and function are not known.
Methods and Results-—We compared patients with type 2 diabetes mellitus (n=751) with different degrees of uncontrolled
metabolic risk factors present with a control group of individuals without present uncontrolled metabolic risk factors as
recommended by the World Health Organization (n=80). In patients with well-controlled metabolic risk factors, only diastolic but
neither structural nor systolic measures were impaired compared to the control group: the (early diastolic mitral inﬂow velocity)/
(atrial diastolic mitral inﬂow velocity) ratio (median 0.94 [interquartile range 0.80, 1.08] versus 1.11 [0.85, 1.38], P<0.001), lateral
early diastolic myocardial velocity at the level of the mitral annulus (mean 9.6 m/s [SD 2.5] versus 10.8 [3.5], P<0.001) and lateral
(early diastolic mitral inﬂow velocity)/(early diastolic myocardial velocity at the level of the mitral annulus) (7.7 [6.5, 10.2] versus
6.3 [4.9, 7.8], P<0.001). With an increasing burden of uncontrolled metabolic risk factors, there were increased left ventricular
mass index and wall thicknesses and impaired systolic function measured as global longitudinal strain: control group 15.9 (2.0);
0 uncontrolled risk factors 15.3 (2.4); 1 to 2 14.6 (2.8); and ≥3 14.0 (2.8), P<0.001. Within the diabetes mellitus group, there
were uni- and multivariable associations of left ventricular measures and systolic blood pressure, body mass index, hemoglobin A1c,
and HDL-cholesterol.
Conclusions-—In patients with type 2 diabetes mellitus, having well-controlled metabolic risk factors was associated with only left
ventricular diastolic impairment but not with either structural or even subtle measures of systolic function. Increasing burden of
uncontrolled metabolic risk factors was associated with structural and functional impairments. ( J Am Heart Assoc. 2018;7:
e008856. DOI: 10.1161/JAHA.118.008856.)
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A dominant feature of type 2 diabetes mellitus (T2D) is itsassociation with the metabolic syndrome, which in the
World Health Organization deﬁnition includes, beyond insulin
resistance, the metabolic risk factors obesity, hypertension,
increased triglycerides and high-density lipoprotein (HDL)-
cholesterol, and albuminuria. Although there is ﬁrm evidence of
an increased risk of cardiovascular disease in patients with
metabolic syndrome,1-3 there has been a strong debate about
whether this is beyond the sum of the contributions of each of
the metabolic risk factors that constitute the syndrome.4 There
is a clear association between the metabolic risk factors
diabetes mellitus,5-7 obesity,8 hypertension9,10 and albumin-
uria11 and the risk of developing heart failure (HF). However,
whether dyslipidemia is associated with HF is less well
elucidated. Nevertheless, in a recent study including 113 554
individuals from the general population, increasing nonfasting
triglyceride was associated with a stepwise increase in the risk
of developing HF.12 These ﬁndings suggest a relationship
between dyslipidemia and the risk of HF. Hence, evidence
indicates that all of the metabolic risk factors in the World
Health Organization deﬁnition of the metabolic syndrome are
associated with an increased risk of developing HF.
For patients with T2D, a distinct effect of diabetes mellitus
on the myocardium, the diabetic cardiomyopathy, has been
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suggested and characterized by a number of previous studies.
They have demonstrated that patients with diabetes mellitus
have increased left ventricular wall thicknesses, left ventric-
ular hypertrophy,13-15 and both decreased systolic and
diastolic function.16-21 We have previously shown that these
changes were ampliﬁed with increasing duration of T2D,
supporting the suggested causal relationship between T2D
and left ventricular (LV) remodeling and functional
measures.22
However, because of the marked association between
metabolic risk factors and diabetes mellitus, and because
both hypertension and obesity have been closely associated
with changes in cardiac mechanics, the direct effect of
diabetes mellitus on the myocardium is difﬁcult to discern
from the effect of the coexisting metabolic risk factors. The
aim of the present study was to examine the association of
the burden of uncontrolled metabolic risk factors with LV
structure and function in patients with T2D receiving multi-
factorial treatment compared to a nondiabetic control group
without or with well-controlled metabolic risk factors. Previ-
ously, we demonstrated an association between triglyceride
level23 and microalbuminuria24 and LV remodeling and
function in this population. Therefore, our aim here was in
addition to examine this association with the remainder of the
metabolic risk factors: obesity, hypertension, hemoglobin A1c
(HbA1c), and HDL-cholesterol levels.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure. However,
researchers may request speciﬁc data and study materials for
the purpose of reproducing the results by contacting the
corresponding author.
Study Population
The Thousand&2 study recruited patients with T2D from 2
large, secondary care centers in Copenhagen, the Capital
Region, Denmark: Steno Diabetes Center and Center for
Diabetes Research, Gentofte Hospital. Details on study
inclusion and study visit have been published previously.24,25
In brief, a total of 2158 patients were invited and 1030
participated in the study. Before attending the examination
the patients ﬁlled out a questionnaire with information on
current medication, previous heart disease (myocardial
infarction, percutaneous coronary intervention, coronary
artery bypass grafting, congestive heart failure, and atrial
ﬁbrillation), previous stroke and peripheral artery disease,
family history of coronary heart disease, smoking habits,
height, and weight. The questionnaire was reviewed with the
patient at the study visit by P.G.J. Blood pressure was
measured in the supine position after at least 15 minutes of
rest. Body mass index (BMI) was calculated (weight [kg]/
height [m]2) based on self-reported measurements.
Patients with atrial ﬁbrillation during the echocardiographic
examination, more than moderate valve disease, and/or
previous heart valve surgery were excluded (n=96). Also, for
the analyses of numbers of metabolic risk factors and relation
to LV structure and function, patients with incomplete
information on BMI, systolic blood pressure, HbA1c, HDL-
cholesterol, triglyceride levels, or albuminuria status were
excluded (n=183).
The study was conducted in accordance with the Decla-
ration of Helsinki, approved by The Danish National Commit-
tee on Biomedical Research Ethics, amendment to protocol
no. H-3-2009-139.26 All participants gave written informed
consent.
The control group consisted of a sample of people from the
Copenhagen City Heart Study, a prospective cohort study of
cardiovascular risk factors in patients from the general
population. Details on the sampling have been published
previously.22 In brief, patients from the Thousand&2 study
were randomly matched 4:1 on age, sex, and systolic blood
pressure with people from the Copenhagen City Heart Study
without diabetes mellitus (n=252). The metabolic risk factors
were measured in all patients with the exception of the
presence of albuminuria. From the control group, people with
known heart disease, atrial ﬁbrillation at the time of the
echocardiographic exam, or presence of any of the metabolic
risk factors as deﬁned above were excluded (n=172). Hence,
the control group consisted of 80 people without diabetes
mellitus, known heart disease, or any of the metabolic risk
Clinical Perspective
What Is New?
• Even with well-controlled metabolic risk factors there is
evidence of diastolic but not systolic or structural cardiac
impairment in patients with type 2 diabetes mellitus.
• With increasing burden of metabolic risk factors, the risk of
further cardiac impairment increases in patients with type 2
diabetes mellitus.
What Are the Clinical Implications?
• Patients with type 2 diabetes mellitus should be considered
for echocardiography even when the metabolic risk factors
are well controlled.
• In assessing patients with type 2 diabetes mellitus, the risk
of cardiac impairment is higher in patients with concomi-
tant uncontrolled metabolic risk factors.
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factors. A ﬂow chart of the derivation of the study population
is provided in Figure 1.
Metabolic Risk Factors
According to the World Health Orgnization deﬁnition of the
metabolic syndrome,27 the metabolic risk factors constitute
T2D or impaired fasting glucose, impaired glucose tolerance,
increased systolic or diastolic blood pressure or antihyper-
tensive treatment, elevated plasma triglycerides, HDL levels,
increased BMI or waist:hip ratio, and presence of albuminuria.
Accordingly, we regarded metabolic risk factors as uncon-
trolled when systolic blood pressure was >140 mm Hg, body
mass index was >30 kg/m2, HbA1c was >48 mmol/L, HDL-
cholesterol was <1.0 mmol/L for women and <0.9 mmol/L
for men, triglyceride was >1.7 mmol/L, and in the presence
of micro- or macroalbuminuria.
Biochemistry
Lipid levels, HbA1c, and creatinine were obtained from routine
blood tests performed at either Steno Diabetes Center or the
Center for Diabetes Research, Herlev and Gentofte Hospital.
Urine albumin/creatinine ratio and/or 24-hour urine albumin
excretion rate are evaluated at least annually at both centers.
Microalbuminuria was deﬁned as a urine albumin/creatinine
ratio between 30 and 300 mg/g or urine albumin excretion
rate between 30 and 300 mg/day, and macroalbuminuria as
a urine albumin/creatinine ratio above 300 mg/g or urine
albumin excretion rate above 300 mg/day on 2 consecutive
measurements.
Echocardiography
Details on the echocardiographic examinations have been
published previously.22-25 In brief, chamber quantiﬁcation was
done in accordance with the recommendations of the
European Association of Echocardiography and the American
Society of Echocardiography.28 LV mass was indexed accord-
ing to height,27 which was chosen in line with our previous
studies. Sphericity index was calculated in end-diastole as LV
length in an apical 4-chamber view/left ventricular internal
diameter in a parasternal long-axis view. LV ejection fraction
was measured with the Simpson biplane method, and reduced
ejection fraction was deﬁned as an LV ejection fraction <50%.
2-Dimensional speckle tracking was performed using GE
EchoPAC software, BT13. Midmyocardial global strain pro-
vided by the software algorithm was used for both longitudinal
and circumferential strain. Global longitudinal strain (GLS) was
the mean value of the GLS from all 3 standard projections.
Global circumferential strain (GCS) was measured at the level
of the papillary muscle. Strain rate was the rate of these
deformations in either longitudinal or circumferential direc-
tions and measured in seconds–1.
People from the Copenhagen City Heart study were
examined with the same echocardiographic protocol as
patients in the Thousand&2 study using Vivid E9 (GE Vingmed
Ultrasound, Horten, Norway).
Statistical Analysis
Continuous variables are presented as mean (SD)/median
(interquartile range) and compared using Welsh t tests or
1-way analysis of variance/Mann-Whitney U tests or Kruskall-
Wallis tests where appropriate. Categorical values are
presented as number (percentage) and compared using chi-
squared tests. Systolic blood pressure, BMI, HbA1c, and HDL-
cholesterol were nonnormally distributed and transformed
using the binary logarithm (log2), after which they were
normally distributed. Association of these and echocardio-
graphic measures were examined using linear regression
models. P-values less than 0.05 on 2-sided tests were
Figure 1. Flowchart of the derivation of the study sample.
DOI: 10.1161/JAHA.118.008856 Journal of the American Heart Association 3
Metabolic Risk Factors and LV in T2D Jørgensen et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on April 10, 2019
considered signiﬁcant. Statistics were performed using R for
Mac, version 3.4.2 (R Project for Statistical Computing,
Vienna University of Economics and Business Administration,
Vienna, Austria).
Results
We identiﬁed 751 patients from the diabetes mellitus cohort
with all metabolic risk factors measured. The distribution of
uncontrolled metabolic risk factors among the patients with
T2D is found in Table 1. We identiﬁed 57 patients without
any or all well-controlled metabolic risk factors after
aggressive multifactorial treatment. Of these, 14% received
b-blockers, 21% angiotensin-converting enzyme inhibitors,
32% angiotensin II receptor blockers, and 28% calcium
antagonists. Also, 72% received metformin, 10% to 21%
received other antidiabetic treatment, and 86% received
statins.
Patients from the diabetesmellitus groupwere further divided
into categories with, respectively, 0 (n=57), 1 to 2 (n=349), and
≥3 (n=345) uncontrolled metabolic risk factors and compared
with the control group (n=80). The population demographics
after this subdivision are shown in Table 2. Compared to the
control group, patients with T2D were of similar age and sex
regardless of the presence of uncontrolled metabolic risk
factors. Blood pressure, both systolic and diastolic, was
insigniﬁcantly higher in patients with T2D compared to the
control group but was signiﬁcantly higher in patients with T2D
with any uncontrolled metabolic risk factor present. Similar
results were seen with for triglyceride levels, but there were
signiﬁcantly higher BMI and lower LDL- andHDL-cholesterol in all
patientswith T2Dcomparedwith the control group.Patientswith
T2D were more often treated with antihypertensive drugs,
diuretics, and statins regardless of the presence of uncontrolled
metabolic risk factors compared with the control group.
Association of Burden of Uncontrolled Metabolic
Risk Factors and Echocardiographic Findings
The associations of numbers of uncontrolled metabolic risk
factors and echocardiographic ﬁndings are found in Table 3.
There was a highly signiﬁcant difference between the control
group, patients with 0, 1 to 2, and ≥3 uncontrolled metabolic
risk factors, and all the structural and diastolic ﬁndings except
LV end-diastolic diameter and left atrial volume index. The
association was less pronounced in the systolic measures
because this was only the case for the proportion with LV
ejection fraction <50% and GLS. Thus, GLS rate, GCS, and
GCS rate were not affected by an increasing number of
uncontrolled metabolic risk factors present.
When the control group is compared with the patients with
T2D without any uncontrolled metabolic risk factor present,
there were no signiﬁcant differences in any structural or
systolic measure, but there was clear evidence of reduced
diastolic function expressed as decreased lateral and septal
early diastolic myocardial velocity at the level of the mitral
annulus and (early diastolic mitral inﬂow velocity)/(early
diastolic myocardial velocity at the level of the mitral annulus),
(early diastolic mitral inﬂow velocity)/(atrial diastolic mitral
inﬂow velocity) ratio, and increased peak early and atrial
diastolic mitral inﬂow velocities. With increasing numbers of
uncontrolled metabolic risk factors present, there was
increasing evidence of both structural remodeling with
increasing LV wall thicknesses and relative wall thicknesses
but no changes in LV end-diastolic diameter or left atrial
volume index. Regarding diastolic measures, there was an
increase in diastolic dysfunction with increasing number of
uncontrolled metabolic risk factors present. With respect to
the systolic measures, GLS was decreased when ≥1 uncon-
trolled risk factor was present and more so when ≥3 were
present, and GLS rate was not affected unless ≥3 uncon-
trolled risk factors were present. There were no differences in
Table 1. Distribution of the Metabolic Risk Factors Present Among Patients With Type 2 Diabetes Mellitus
Number of Uncontrolled Metabolic Risk Factors Present
0 (n=57) 1 (n=137) 2 (n=212) 3 (n=170) 4 (n=120) 5 (n=43) 6 (n=12)
Elevated systolic blood pressure, n (%) 0 (0) 8 (6) 46 (22) 63 (37) 61 (51) 31 (72) 12 (100)
Elevated BMI, n (%) 0 (0) 17 (12) 75 (35) 99 (58) 91 (76) 40 (93) 12 (100)
Elevated HDL-cholesterol, n (%) 0 (0) 7 (5) 13 (6) 34 (20) 44 (37) 30 (70) 12 (100)
Elevated triglyceride, n (%) 0 (0) 24 (18) 87 (41) 122 (72) 102 (85) 43 (100) 12 (100)
Albuminuria, n (%) 0 (0) 7 (5) 35 (17) 47 (28) 66 (55) 30 (70) 12 (100)
Elevated hemoglobin A1c, n (%) 0 (0) 74 (54) 168 (79) 145 (85) 116 (97) 41 (95) 12 (100)
Criteria for metabolic risk factors: hemoglobin A1c >48 mmol/L, systolic blood pressure >140 mm Hg, body mass index >30 kg/m
2, HDL-cholesterol <1.0 mmol/L for women and
<0.9 mmol/L for men, triglycerides >1.7 mmol/L, and presence of micro- or macroalbuminuria. BMI indicates body mass index; HDL, high-density lipoprotein.
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Table 2. Population Demographics
Control
Group
Type 2 Diabetes Mellitus and
P Value
(Across
All Groups)
P Value
(Control vs 0
Risk Factors)
P Value
(Control vs 1
to 2 Risk
Factors)
P Value
(Control
vs ≥3 Risk
Factors)
0 Uncontrolled
Risk Factors
1 to 2
Uncontrolled
Risk Factors
≥3
Uncontrolled
Risk Factors
n=80 n=57 n=349 n=345
Clincal
Age, y 63 [57, 68] 65 [59, 72] 65 [59, 71] 65 [57, 70] 0.03 0.17 0.005* 0.11
Male sex, % 52 (65.0) 32 (56.1) 233 (66.8) 231 (67.0) 0.44 0.38 0.87 0.84
Diabetes
mellitus
duration, y
7 [2, 15] 11 [5, 17] 13 [8, 20]
Body mass
index, kg/m2
24.1
[22. 8, 26.1]
26.0
[23.5, 27.8]
27.7 [25.3, 30.4] 32.3 [29.0, 35.5] <0.001* 0.004* <0.001* <0.001*
Systolic blood
pressure,
mm Hg
123 (9) 126 (10) 132 (16) 142 (18) <0.001* 0.09 <0.001* <0.001*
Diastolic blood
pressure,
mm Hg
76 (10) 77 (8) 78 (10) 82 (11) <0.001* 0.37 0.05* <0.001*
Coronary heart
disease, %
10 (17.5) 58 (16.6) 63 (18.3)
Laboratory values
LDL-cholesterol,
mmol/L
3.1 [2.6, 3.5] 1.9 [1.6, 2.3] 2.0 [1.6, 2.6] 2.0 [1.5, 2.6] <0.001* <0.001* <0.001* <0.001*
HDL-cholesterol,
mmol/L
1.7 [1.5, 2.0] 1.5 [1.2, 1.8] 1.2 [1.0, 1.5] 1.0 [0.9, 1.3] <0.001* 0.006 <0.001* <0.001*
Triglyceride,
mmol/L
1.0 [0.8, 1.3] 1.1 [0.8, 1.3] 1.4 [1.0, 2.0] 2.3 [1.8, 3.1] <0.001* 0.45 <0.001* <0.001*
Albuminuria, % 42 (12.0) 155 (44.9)
Microalbuminuria,
%
37 (10.6) 100 (29.0)
Macroalbuminuria,
%
5 (1.4) 55 (15.9)
Hemoglobin
A1c, mmol/mol
43 [40, 46] 54 [46, 62] 60 [53, 73]
Hemoglobin
A1c, %
6.1 (0.4) 7.3 (1.3) 8.0 (1.5)
Creatinine,
lmol/L
78 [71, 87] 72 [63, 84] 77 [66, 92] 82 [65, 103] 0.01 0.06 0.72 0.19
Medication
Metformin, % 41 (71.9) 251 (71.9) 252 (73.0)
DPP4
inhibitors, %
7 (12.3) 30 (8.6) 35 (10.1)
Sulfonylurea, % 6 (10.5) 58 (16.6) 51 (14.8)
Glucagon-like
peptide
1-receptor
agonist, %
11 (19.3) 63 (18.1) 103 (29.9)
Insulin, % 12 (21.1) 159 (45.6) 201 (58.3)
b-Blockers, % 8 (10.0) 8 (14.0) 80 (22.9) 94 (27.2) <0.001* 0.002* <0.001* <0.001*
Continued
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LV ejection fraction, GCS, or GCS rate with increasing number
of uncontrolled metabolic risk factors present.
Figure 2 shows how LV structural, diastolic, and systolic
measures were affected with increasing numbers of uncon-
trolled metabolic risk factors present. Here, these patterns
are repeated: there was diastolic but not structural or systolic
impairment without concomitant metabolic risk factors.
Structural and systolic impairment emerged as numbers of
uncontrolled metabolic risk factors increased.
Association of Systolic Blood Pressure, BMI,
HbA1c, and HDL-Cholesterol With
Echocardiographic Findings in Patients With T2D
Univariable and multivariable associations of systolic blood
pressure, BMI, HbA1c, HDL-cholesterol, and echocardio-
graphic ﬁndings are found in Tables 4 and 5. In general,
there was an overall association with LV structural mea-
sures (LV mass index [not for HbA1c], LV wall thicknesses,
and relative wall thickness [not for HDL-cholesterol]). This,
however, was attenuated overall for HbA1c and HDL-
cholesterol but persisted for systolic blood pressure and
BMI after adjustment for the other metabolic risk factors.
Regarding diastolic measures, they were consistently asso-
ciated with systolic blood pressure and BMI, in particular
evidence of elevated ﬁlling pressures expressed as (early
diastolic mitral inﬂow velocity)/(early diastolic myocardial
velocity at the level of the mitral annulus) and decreased LV
relaxation expressed as lateral early diastolic myocardial
velocity at the level of the mitral annulus. On the other
hand, there was no consistent pattern of association
between either HbA1c or HDL-cholesterol and diastolic
measures. For the systolic measures, all metabolic risk
factors were univariably associated with GLS, but after
adjustment for the other metabolic risk factors, there was a
signiﬁcant association only with BMI. Interestingly, after
adjusting, where BMI was associated with both GLS and
GCS and not their corresponding rates, the opposite was
the case for systolic blood pressure. Other than that, there
was no clear pattern of associations between either and the
systolic LV measures except LV ejection fraction, which
increased with HDL-cholesterol in both uni- and multivari-
able analyses.
Discussion
The primary ﬁndings in this study were that in patients with
T2D with well-controlled metabolic risk factors, there was
evidence of cardiac impairment characterized only by diastolic
dysfunction with neither structural changes nor systolic
dysfunction. Furthermore, with an increasing number of
uncontrolled metabolic risk factors present, there was also
a progressive impairment of LV structure and LV systolic
(longitudinal) function. Hence, despite reaching treatment
goals in patients with T2D and eliminating the contribution of
the metabolic risk factors, we were still able to identify an
effect on the myocardium characterized only by impaired
diastolic functional measures.
Table 2. Continued
Control
Group
Type 2 Diabetes Mellitus and
P Value
(Across
All Groups)
P Value
(Control vs 0
Risk Factors)
P Value
(Control vs 1
to 2 Risk
Factors)
P Value
(Control
vs ≥3 Risk
Factors)
0 Uncontrolled
Risk Factors
1 to 2
Uncontrolled
Risk Factors
≥3
Uncontrolled
Risk Factors
n=80 n=57 n=349 n=345
Angiotensin-
converting
enzyme
inhibitors, %
5 (6.2) 12 (21.1) 144 (41.3) 128 (37.1) <0.001* 0.12 <0.001* <0.001*
Angiotensin II
receptor
blockers, %
8 (10.0) 18 (31.6) 125 (35.8) 163 (47.2) <0.001* <0.001* <0.001* <0.001*
Calcium
antagonists, %
8 (10.0) 16 (28.1) 111 (31.8) 120 (34.8) <0.001* 0.01* <0.001* <0.001*
Diuretics, % 8 (10.0) 23 (40.4) 155 (44.4) 204 (59.1) <0.001* <0.001* <0.001* <0.001*
Statins, % 8 (10.0) 49 (86.0) 278 (79.7) 263 (76.2) <0.001* <0.001* <0.001* <0.001*
Criteria for uncontrolled metabolic risk factors include hemoglobin A1c >48 mmol/L, systolic blood pressure >140 mm Hg, body mass index >30 kg/m
2, HDL-cholesterol <1.0 mmol/L
for women and <0.9 mmol/L for men, triglycerides >1.7 mmol/L, and presence of micro- or macroalbuminuria. Continuous traits are reported as mean (SD) or median [interquartile range]
in case of nonnormal distribution. DPP4 indicates dipeptidyl peptidase-4; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*P<0.05.
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Table 3. Association of Number of Uncontrolled Metabolic Risk Factors and Echocardiographic Findings
Control Group
Type 2 Diabetes Mellitus and
P Value
(Across
All Groups)
P Value
(Control
vs 0 Risk
Factors)
P Value
(Control
vs 1 to 2
Risk
Factors)
P Value
(Control
vs ≥3 Risk
Factors)
0 Uncontrolled
Risk Factors
1 to 2
Uncontrolled
Risk Factors
≥3
Uncontrolled
Risk Factors
n=80 n=57 n=349 n=345
Structural measures
Left ventricular
mass index, g/m2.7
35.5 (8.0) 35.5 (9.6) 37.1 (11.7) 41.1 (11.1) <0.001* 0.99 0.26 <0.001*
Interventricular
septum thickness,
mm
10.0 (1.3) 9.9 (1.4) 10.4 (1.8) 11.2 (1.7) <0.001* 0.87 0.06 <0.001*
End-diastolic
internal diameter,
mm
46.8 (4.8) 46.0 (6.8) 45.6 (6.3) 45.9 (6.0) 0.51 0.43 0.13 0.21
Posterior wall
thickness, mm
9.4 (1.3) 9.5 (1.2) 10.1 (1.5) 10.8 (1.6) <0.001* 0.76 <0.001* <0.001*
Relative wall thickness 0.41 (0.07) 0.42 (0.07) 0.45 (0.09) 0.48 (0.10) <0.001* 0.26 <0.001* <0.001*
Sphericity index 0.17 (0.02) 0.17 (0.02) 0.18 (0.03) 0.18 (0.03) 0.17 0.60 0.11 0.05*
Left atrial end-systolic
volume index, mL/m2
26 [22, 32] 26 [21, 31] 25 [20, 32] 25 [20, 31] 0.81 0.82 0.79 0.56
Diastolic measures
Peak E velocity, m/s 0.67 [0.55, 0.78] 0.74 [0.63, 0.87] 0.75 [0.63, 0.87] 0.76 [0.65, 0.88] <0.001* 0.01* <0.001* <0.001*
Peak A velocity, m/s 0.60 (0.16) 0.79 (0.19) 0.85 (0.19) 0.86 (0.20) <0.001* <0.001* <0.001* <0.001*
E/A ratio 1.11 [0.85, 1.38] 0.94 [0.80, 1.08] 0.86 [0.75, 1.07] 0.87 [0.75, 1.06] <0.001* 0.005* <0.001* <0.001*
E deceleration
time, ms
191 [164, 219] 209 [168, 247] 220 [183, 263] 220 [188, 269] <0.001* 0.14 <0.001* <0.001*
Lateral e0
(per second)
10.8 (3.5) 9.6 (2.5) 8.7 (2.6) 8.5 (2.5) <0.001* 0.03* <0.001* <0.001*
Septal e0, m/s 8.4 (2.7) 7.2 (1.8) 6.8 (1.9) 6.5 (1.8) <0.001* 0.002* <0.001* <0.001*
E/e0 lateral 6.3 [4.9, 7.8] 7.7 [6.5, 10.2] 8.6 [6.9, 10.6] 9.0 [7.2, 12.1] <0.001* <0.001* <0.001* <0.001*
E/e0septal 7.7 [6.6, 9.9] 10.5 [8.6, 12.4] 10.9 [9.2, 13.3] 11.6 [9.6, 14.9] <0.001* <0.001* <0.001* <0.001*
Systolic measures
Ejection fraction, % 61 [56, 65] 62 [57, 66] 61 [57, 65] 60 [55, 65] 0.14 0.52 0.96 0.24
Reduced ejection
fraction (<50%), %
5 (6.5) 2 (3.6) 34 (9.9) 48 (14.4) 0.03* 0.73 0.48 0.09
Global longitudinal
systolic strain, %
15.9 (2.0) 15.3 (2.4) 14.6 (2.8) 14.0 (2.8) <0.001* 0.13 <0.001* <0.001*
Global longitudinal
systolic strain rate
(per second)
0.81 (0.11) 0.80 (0.14) 0.79 (0.17) 0.77 (0.18) 0.09 0.53 0.37 0.04*
Global circumferential
systolic strain, %
18.1 (4.1) 18.7 (4.8) 18.0 (5.2) 17.4 (5.3) 0.34 0.49 0.87 0.35
Global circumferential
systolic strain rate
(per second)
0.97 (0.22) 0.99 (0.28) 1.05 (0.33) 1.03 (0.34) 0.27 0.71 0.07 0.19
Criteria for uncontrolled metabolic risk factors include hemoglobin A1c >48 mmol/L, systolic blood pressure >140 mm Hg, body mass index >30 kg/m
2, HDL-cholesterol <1.0 mmol/L
for women and <0.9 mmol/L for men, triglyceride >1.7 mmol/L, and presence of micro- or macroalbuminuria. Continuous traits are reported as mean (SD) or median [interquartile range]
in case of nonnormal distribution. A indicates atrial diastolic mitral inﬂow velocity; E, early diastolic mitral inﬂow velocity; e0 , early diastolic myocardial velocity at the level of the mitral
annulus.
*P<0.05.
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Metabolic Risk Factors and LV Structure and
Function in T2D
We found that in patients with well-controlled metabolic risk
factors there was no evidence of structural or systolic
impairment of the LV. This is in contrast to previous studies
that have demonstrated the presence of both structural and
systolic in addition to diastolic impairment in patients with
T2D. The Strong Heart Study demonstrated increased LV wall
thicknesses, LV mass index, and decreased fractional short-
ening in a population of American Indians with a high
prevalence of T2D.14 The same tendency was found in
hypertensive patients in the HyperGEN study, in which T2D
was associated with increased LV mass and wall thick-
nesses,15 and in the ARIC study, in which increasing levels of
HbA1c were associated with LV mass, wall thicknesses, GLS,
and diastolic measures including septal and lateral early
diastolic myocardial velocity at the level of the mitral annulus
and (early diastolic mitral inﬂow velocity)/(early diastolic
myocardial velocity at the level of the mitral annulus).29
Additionally, Ernande et al compared 144 patients with T2D
without cardiac disease with 88 healthy controls without T2D,
hypertension, low levels of total and LDL-cholesterol, high
levels of HDL-cholesterol, and normal renal function and found
that T2D was associated with decreased systolic function
expressed as radial and longitudinal strain and strain rate.18
The same group also concluded in a different analysis that the
deformation changes were closely associated with increased
LV wall thicknesses associated with T2D.19 Common among
these studies is that there were differences between the
compared groups regarding BMI (Strong, ARIC, HyperGEN, and
Ernande), systolic blood pressure (Strong, HyperGEN,
and Ernande), and lipid levels (ARIC, HyperGEN, and Ernande),
and although adjusted models were constructed, the complex
interaction of obesity, blood pressure, and lipid levels is
difﬁcult to examine fully in any of these cohorts. Hence, our
study indicates that the presence of other metabolic risk
factors in T2D accounts for the structural changes found in
T2D and possibly therefore for the changes in systolic function
as suggested in the abovementioned study by Ernande et al.19
Thus, our ﬁndings suggest that the previously found effect of
diabetes mellitus on LV structural and systolic function may
have been caused by the presence of confounding, concomi-
tant metabolic risk factors. Recently, this complex interaction
was addressed in a study that suggested cardiac phenotypes
in patients with T2D. This was based on cluster analysis and
found that obesity and hypertension were particularly associ-
ated with worse prognosis in women, whereas in the case of
Figure 2. Association of number of uncontrolled metabolic risk factors and measures of left ventricular structural and systolic and diastolic
measures. e0, early diastolic myocardial velocity; E/e0, ratio of early mitral inﬂow velocity and early diastolic myocardial velocity; LVEF, left
ventricular ejection fraction.
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men this was seen with LV hypertrophy and systolic dysfunc-
tion.30 Surprisingly, there was no association of left atrial size
and increasing burden of uncontrolled metabolic risk factors.
This is contradictory to what we would expect because of the
strong association of the burden of uncontrolled metabolic risk
factors and diastolic dysfunction. Our results suggest that left
atrial size was inﬂuenced by other unmeasured confounding
factors in this population.
Table 4. Univariable Association of Systolic Blood Pressure, BMI, HbA1c, HDL-Cholesterol, and Echocardiographic Findings in
Patients With T2D
Log2 (Systolic Blood Pressure) Log2 (BMI) Log2 (HbA1c) Log2 (HDL-Cholesterol)
b-Coefﬁcient
(SE) P Value
b-coefﬁcient
(SE) P Value
b-Coefﬁcient
(SE) P Value b-Coefﬁcient (SE) P Value
Structural measures
Left ventricular
mass index, g/m2.7
11.5 (2.3) <0.001* 15.3 (1.5) <0.001* 0.02 (1.2) 0.98 3.8 (1.0) <0.001*
Interventricular
septum diameter,
mm
1.3 (0.4) <0.001* 1.6 (0.2) <0.001* 0.5 (0.2) 0.003* 0.7 (0.2) <0.001*
End-diastolic
internal diameter,
mm
1.1 (1.3) 0.41 4.3 (0.9) <0.001* 1.6 (0.6) 0.01* 2.1 (0.5) <0.001*
Posterior wall
diameter (mm)
1.3 (0.3) <0.001* 1.6 (0.2) <0.001* 0.3 (0.2) 0.07 0.7 (0.1) <0.001*
Relative wall
thickness
0.05 (0.02) 0.01* 0.03 (0.01) 0.04* 0.03 (0.01) 0.002* 0.01 (0.01) 0.27
Sphericity index
(per 0.01 increase)
0.24 (0.55) 0.66 0.58 (0.38) 0.13 0.46 (0.27) 0.08 0.08 (0.23) 0.72
Left atrial end-systolic
volume index, mL/m2
4.4 (1.7) 0.01* 1.0 (1.2) 0.38 1.7 (0.8) 0.04* 0.2 (0.7) 0.78
Diastolic measures
Peak E velocity (cm/s) 0.18 (0.04) <0.001* 0.11 (0.03) 0.0001* 0.00 (0.02) 0.99 0.001 (0.02) 0.97
Peak A velocity, cm/s 0.29 (0.04) <0.001* 0.07 (0.03) 0.009* 0.03 (0.02) 0.12 0.03 (0.02) 0.08
E/A ratio 0.10 (0.06) 0.09 0.05 (0.04) 0.25 0.03 (0.03) 0.32 0.03 (0.02) 0.19
E deceleration time, ms 4.0 (15.5) 0.80 10.2 (10.5) 0.33 16.0 (7.3) 0.03* 3.4 (6.5) 0.60
Lateral e0, cm/s 2.4 (0.5) <0.001* 0.7 (0.4) 0.04* 0.5 (0.3) 0.03* 0.15 (0.2) 0.52
Septal e0, cm/s 1.1 (0.4) 0.004* 0.2 (0.3) 0.40 0.4 (0.2) 0.05 0.1 (0.2) 0.40
E/e0 lateral 6.0 (0.9) <0.001* 2.1 (0.6) 0.002* 0.6 (0.5) 0.22 0.3 (0.4) 0.46
E/e0septal 5.4 (1.1) <0.001* 2.1 (0.7) 0.003* 1.0 (0.5) 0.05* 0.2 (0.5) 0.68
Systolic measures
Ejection fraction, % 0.8 (1.7) 0.65 2.9 (1.2) 0.02* 0.8 (0.9) 0.35 3.1 (0.7) <0.001*
Global longitudinal
systolic strain, %
1.2 (0.6) 0.05* 1.8 (0.4) <0.001* 0.6 (0.3) 0.03* 1.0 (0.2) <0.001*
Global longitudinal
systolic strain rate
(per second)
0.11 (0.04) 0.003* 0.05 (0.03) 0.04* 0.02 (0.02) 0.37 0.03 (0.02) 0.09
Global circumferential
systolic strain, %
1.3 (1.2) 0.28 2.6 (0.9) 0.003* 0.3 (0.6) 0.61 0.7 (0.5) 0.19
Global circumferential
systolic strain rate (s1)
0.2 (0.08) 0.01* 0.01 (0.05) 0.79 0.01 (0.04) 0.75 0.01 (0.03) 0.82
A indicates atrial diastolic mitral inﬂow velocity; BMI, body mass index; E, early diastolic mitral inﬂow velocity; e0 , early diastolic myocardial velocity at the level of the mitral annulus; HbA1c,
hemoglobin A1c; HDL, high-density lipoprotein; SE, standard error; T2D, type 2 diabetes mellitus.
*P<0.05.
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Metabolic Syndrome and LV Mechanics
In this study we conﬁrmed the association of systolic blood
pressure, BMI, and HbA1c with LV structure and function. Also,
we found an undescribed but also rather inconsistent
association of HDL-cholesterol and LV structure and function.
Previous studies have established a close relation between
hypertension, obesity, andHbA1c and LV structure and function.
The association of hypertension and LV hypertrophy is 1 of the
earliest described in cardiology and is caused by pressure
Table 5. Multivariable Association of Systolic Blood Pressure, Body Mass Index, HbA1c, HDL-Cholesterol, and Echocardiographic
Findings in Patients With T2D
Log2 (Systolic Blood Pressure) Log2 (BMI) Log2 (Hemoglobin A1c) Log2 (HDL-Cholesterol)
b-Coefﬁcient
(SE) P Value
b-Coefﬁcient
(SE) P Value
b-Coefﬁcient
(SE) P Value
b-Coefﬁcient
(SE) P Value
Structural measures
Left ventricular
mass index, g/m2.7
6.9 (2.2) 0.002* 15.2 (1.6) <0.001* 1.8 (1.1) 0.09 2.6 (1.1) 0.02*
Interventricular
septum diameter, mm
0.8 (0.3) 0.01* 1.5 (0.2) <0.00*1 0.3 (0.2) 0.09 0.1 (0.2) 0.50
End-diastolic
internal diameter,
mm
1.6 (1.3) 0.20 4.2 (0.9) <0.001* 1.8 (0.6) 0.004* 1.2 (0.6) 0.06
Posterior wall
diameter, mm
0.9 (0.3) 0.004* 1.6 (0.2) <0.001* 0.03 (0.1) 0.84 0.1 (0.1) 0.32
Relative wall
thickness
0.02 (0.02) 0.29 0.03 (0.01) 0.03* 0.02 (0.01) 0.02* 0.01 (0.01) 0.46
Sphericity index
(per 0.01 increase)
0.55 (1.09) 0.61 0.79 (0.41) 0.05 0.42 (0.29) 0.15 0.31 (0.28) 0.26
Left atrial end-systolic
volume index, mL/m2
3.8 (1.7) 0.03* 0.4 (1.2) 0.77 1.6 (0.8) 0.06 0.5 (0.8) 0.56
Diastolic measures
Peak E velocity, cm/s 0.15 (0.04) <0.001* 0.10 (0.03) <0.001* 0.01 (0.02) 0.58 0.02 (0.02) 0.38
Peak A velocity, cm/s 0.21 (0.04) <0.001* 0.08 (0.03) 0.003* 0.03 (0.02) 0.09 0.01 (0.02) 0.42
E/A ratio 0.04 (0.06) 0.52 0.02 (0.04) 0.70 0.04 (0.03) 0.12 0.00 (0.03) 0.98
E deceleration
time, ms
19.3 (15.6) 0.22 21.0 (11.0) 0.06 17.2 (7.4) 0.02* 2.8 (7.5) 0.71
Lateral e0, cm/s 1.1 (0.5) 0.02* 1.1 (0.3) 0.002* 0.4 (0.2) 0.05 0.4 (0.2) 0.12
Septal e0, cm/s 0.2 (0.4) 0.53 0.5 (0.3) 0.05 0.3 (0.2) 0.06 0.4 (0.2) 0.02*
E/e0 lateral 4.1 (0.9) <0.001* 2.0 (0.6) 0.002* 0.2 (0.4) 0.60 1.1 (0.4) 0.02*
E/e0septal 3.3 (1.0) 0.001* 2.3 (0.7) 0.002* 0.4 (0.5) 0.13 1.0 (0.5) 0.04*
Systolic measures
Ejection fraction, % 0.5 (1.8) 0.77 2.2 (1.3) 0.09 0.3 (0.9) 0.72 2.3 (0.9) 0.01*
Global longitudinal
systolic strain, %
0.6 (0.6) 0.29 1.7 (0.4) <0.001* 0.4 (0.3) 0.17 0.6 (0.3) 0.05
Global longitudinal
systolic strain rate, s–1
0.08 (0.04) 0.03* 0.05 (0.03) 0.07 0.01 (0.02) 0.58 0.04 (0.02) 0.04*
Global circumferential
systolic strain, %
0.9 (1.3) 0.46 2.3 (0.9) 0.01* 0.07 (0.6) 0.91 0.1 (0.6) 0.82
Global circumferential
systolic strain rate, s–1
0.17 (0.08) 0.04* 0.03 (0.06) 0.59 0.02 (0.04) 0.63 0.05 (0.04) 0.25
Multivariable model adjusted for age, sex, hemoglobin A1c, body mass index, systolic blood pressure, HDL-cholesterol, triglyceride level, and albuminuria. A indicates atrial diastolic mitral
inﬂow velocity; BMI, body mass index; E, early diastolic mitral inﬂow velocity; e0 , early diastolic myocardial velocity at the level of the mitral annulus; HDL, high-density lipoprotein; SE,
standard error.
*P<0.05.
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overload of the LV.9 When present, LV hypertrophy is closely
related to prognosis whether detected by electrocardiography,31
echocardiography,32 or magnetic resonance imaging,33 and
regression of LV hypertrophy in serial ECGs has also been linked
to improved prognosis.34,35 In obesity, there is a strong
association of both diastolic and systolic dysfunction that
seems to be related to obesity severity,36 and regarding
dysglycemia, a close relationship of HbA1c with LV mechanics
exists even in elderly patients without overt diabetesmellitus.29
The same is the case for low-grade states of albuminuria.37
Thus, we have previously described a close association of
LV structure and function with both microalbuminuria and
increasing levels of triglycerides in this cohort,23,24 and there is
convincing evidence that all components of the metabolic
syndrome have an impact on the myocardium.
Strengths and Limitations
The strength of this study is the size of the cohort, which
enables stratiﬁcation of patients in groups with increasing
burden of uncontrolled metabolic risk factors present (except
that only 12 patients had all metabolic risk factors uncon-
trolled). In addition, all patients and the control group
underwent comprehensive echocardiography. Some limita-
tions of this study must be acknowledged. A hallmark of the
metabolic syndrome is increased waist circumference, which
was not measured in this study, and thus, BMI was used as the
only measure of obesity. Albuminuria was not assessed in the
control group, and we were not able to exclude people with
this metabolic risk factor from the control group. Another
limitation is that only patients from specialized diabetes
mellitus clinics were included in the study, thus limiting the
interpretability to T2D patients followed in primary care.
Although the presented diastolic measures are the most
commonly used, other diastolic measurements, including
strain rate during isovolumetric relaxation and ratio of early
diastolic mitral inﬂow velocity and strain rate during isovolu-
metric relaxation,38 may be more sensitive markers of diastolic
dysfunction and were not measured in this cohort. In addition,
we were not able to evaluate the association of biomarkers of
cardiac function, in particular NT-pro–brain natriuretic peptide.
Also, HDL functionality, eg, macrophage cholesterol efﬂux,
which is considered to be the main determinant of the
beneﬁcial effect of HDL-cholesterol, was not measured.39
Finally, because this is an observational study, no inferences
on causality can be drawn from the data.
Conclusion
In this study we have shown that patients with T2D and well-
controlled metabolic risk factors had impaired diastolic
function but preserved LV structure and systolic function.
This was in contrast to previous studies that had not
excluded patients with present metabolic risk factors.
Because the burden of uncontrolled metabolic risk factors
increased, increasing LV structural and systolic changes
emerged, further indicating that these changes are predom-
inantly caused by an effect of concomitant metabolic risk
factors.
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